Trade Assembly Biosciences, Inc. - ASMB CFD

Add to favourite

13.3974

1.98%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.2952

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.001

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Assembly Biosciences Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	13.1374
Open*	13.3074
1-Year Change*	1146.36%
Day's Range*	13.2574 - 13.6974
52 wk Range	0.64-1.78
Average Volume (10 days)	251.38K
Average Volume (3 months)	12.71M
Market Cap	52.63M
P/E Ratio	-100.00K
Shares Outstanding	65.79M
Revenue	N/A
EPS	-1.43
Dividend (Yield %)	N/A
Beta	0.52
Next Earnings Date	Mar 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	13.1374	0.6600	5.29%	12.4774	13.3274	12.1074
Apr 17, 2024	12.8074	-1.5900	-11.04%	14.3974	14.4274	12.5074
Apr 16, 2024	14.5074	0.0100	0.07%	14.4974	14.7474	14.3474
Apr 15, 2024	14.6474	-0.0100	-0.07%	14.6574	15.0974	14.3474
Apr 12, 2024	14.6474	-0.1000	-0.68%	14.7474	14.9974	14.3474
Apr 11, 2024	14.9974	0.7100	4.97%	14.2874	14.9974	14.2874
Apr 10, 2024	14.6674	0.4700	3.31%	14.1974	14.6674	13.8974
Apr 9, 2024	14.7474	0.3400	2.36%	14.4074	14.9474	13.9974
Apr 8, 2024	14.1474	0.3700	2.69%	13.7774	14.4974	13.7774
Apr 5, 2024	13.8674	0.6700	5.08%	13.1974	14.2074	13.0274
Apr 4, 2024	13.3574	-0.1500	-1.11%	13.5074	14.1074	13.2974
Apr 3, 2024	13.4074	0.4300	3.31%	12.9774	14.3474	12.9774
Apr 2, 2024	13.3474	0.3500	2.69%	12.9974	13.4874	12.7974
Apr 1, 2024	12.8974	-0.4000	-3.01%	13.2974	13.2974	12.8974
Mar 28, 2024	13.2474	0.2400	1.85%	13.0074	13.4474	12.9974
Mar 27, 2024	13.3074	0.5800	4.56%	12.7274	13.3674	12.7174
Mar 26, 2024	12.8474	-0.4500	-3.38%	13.2974	13.3974	12.7374
Mar 25, 2024	12.9974	0.4900	3.92%	12.5074	13.3674	12.5074
Mar 22, 2024	12.5474	0.5500	4.58%	11.9974	12.8474	11.9974
Mar 21, 2024	12.1574	0.3000	2.53%	11.8574	12.6074	11.8474

Assembly Biosciences, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Assembly Biosciences Inc Earnings Release Q1 2024 Assembly Biosciences Inc Earnings Release Forecast - Previous -
Friday, May 24, 2024
Time (UTC) 15:00	Country US	Event Assembly Biosciences Inc Annual Shareholders Meeting Assembly Biosciences Inc Annual Shareholders Meeting Forecast - Previous -
Wednesday, August 7, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Assembly Biosciences Inc Earnings Release Q2 2024 Assembly Biosciences Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	6.254	79.105	15.963	14.804
Total Operating Expense	94.114	138.942	143.881	118.676	107.539
Selling/General/Admin. Expenses, Total	23.906	28.503	36.86	32.919	34.798
Research & Development	69.111	70.149	101.337	85.757	72.741
Operating Income	-94.114	-132.688	-64.776	-102.713	-92.735
Interest Income (Expense), Net Non-Operating	1.022	0.302	2.624	4.3	3.083
Net Income Before Taxes	-93.092	-132.386	-62.152	-98.408	-89.652
Net Income After Taxes	-93.092	-129.855	-62.152	-97.634	-90.751
Net Income Before Extra. Items	-93.092	-129.855	-62.152	-97.634	-90.751
Net Income	-93.092	-129.855	-62.152	-97.634	-90.751
Income Available to Common Excl. Extra. Items	-93.092	-129.855	-62.152	-97.634	-90.751
Income Available to Common Incl. Extra. Items	-93.092	-129.855	-62.152	-97.634	-90.751
Diluted Net Income	-93.092	-129.855	-62.152	-97.634	-90.751
Diluted Weighted Average Shares	48.4093	43.2804	35.4271	26.2588	22.8016
Diluted EPS Excluding Extraordinary Items	-1.92302	-3.00032	-1.75436	-3.71815	-3.98002
Diluted Normalized EPS	-1.90036	-2.39523	-1.59392	-3.71815	-3.98002
Revenue	0	6.254	79.105	15.963	14.804
Total Extraordinary Items
Other, Net				0.005
Unusual Expense (Income)	1.097	40.29	5.684

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Revenue			0	0
Total Operating Expense	17.488	19.559	22.978	23.401	24.573
Selling/General/Admin. Expenses, Total	4.965	5.012	5.897	5.271	6.781
Research & Development	12.523	14.547	15.984	18.13	17.792
Unusual Expense (Income)			1.097
Operating Income	-17.488	-19.559	-22.978	-23.401	-24.573
Interest Income (Expense), Net Non-Operating	0.592	0.609	0.583	0.256	0.112
Net Income Before Taxes	-16.896	-18.95	-22.395	-23.145	-24.461
Net Income After Taxes	-16.896	-18.95	-22.395	-23.145	-24.461
Net Income Before Extra. Items	-16.896	-18.95	-22.395	-23.145	-24.461
Net Income	-16.896	-18.95	-22.395	-23.145	-24.461
Income Available to Common Excl. Extra. Items	-16.896	-18.95	-22.395	-23.145	-24.461
Income Available to Common Incl. Extra. Items	-16.896	-18.95	-22.395	-23.145	-24.461
Diluted Net Income	-16.896	-18.95	-22.395	-23.145	-24.461
Diluted Weighted Average Shares	52.2601	51.0125	48.7686	48.4484	48.2935
Diluted EPS Excluding Extraordinary Items	-0.32331	-0.37148	-0.45921	-0.47772	-0.50651
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.32331	-0.37148	-0.43672	-0.47772	-0.50651

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	96.967	154.204	224.493	282.78	222.502
Cash and Short Term Investments	91.61	146.627	216.413	274.043	218.08
Cash & Equivalents	52.418	45.627	59.444	46.732	41.471
Short Term Investments	39.192	101	156.969	227.311	176.609
Prepaid Expenses	4.413	7.241	6.85	5.363	1.992
Total Assets	101.794	191.06	283.254	339.907	268.045
Property/Plant/Equipment, Total - Net	3.938	7.181	10.731	13.805	0.557
Property/Plant/Equipment, Total - Gross	5.625	8.388	12.567	15.005	1.614
Accumulated Depreciation, Total	-1.687	-1.207	-1.836	-1.2	-1.057
Goodwill, Net		0	12.638	12.638	12.638
Intangibles, Net		0	29	29	29
Long Term Investments	0	27.972
Total Current Liabilities	16.296	16.073	24.433	24.44	18.472
Accounts Payable	2.493	2.659	4.598	1.731	3.693
Accrued Expenses	13.803	13.414	19.835	16.298	9.679
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	19.13	22.131	42.676	66.69	57.392
Total Long Term Debt	0	0	0	0	0
Deferred Income Tax		0	2.531	2.531	3.252
Total Equity	82.664	168.929	240.578	273.217	210.653
Preferred Stock - Non Redeemable, Net	0	0		0	0
Common Stock	0.049	0.048	0.034	0.032	0.025
Additional Paid-In Capital	807.938	800.728	742.387	712.807	552.762
Retained Earnings (Accumulated Deficit)	-724.52	-631.428	-501.573	-439.421	-341.787
Unrealized Gain (Loss)	-0.803	-0.419	-0.27	-0.201	-0.347
Total Liabilities & Shareholders’ Equity	101.794	191.06	283.254	339.907	268.045
Total Common Shares Outstanding	48.895	48.1204	34.0267	32.5583	25.4954
Total Receivables, Net	0.944	0.336	1.23	3.374	2.43
Accounts Receivable - Trade, Net	0.944	0.336	1.23	3.374	2.43
Other Current Liabilities, Total			0	6.411	5.1
Other Liabilities, Total	2.834	6.058	15.712	39.719	35.668
Other Long Term Assets, Total	0.889	1.703	6.392	1.684	3.348
Total Preferred Shares Outstanding	0	0	0	0	0

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	49.672	64.081	79.744	96.967	115.078
Cash and Short Term Investments	46.21	59.831	73.016	91.61	108.651
Cash & Equivalents	26.656	21.623	43.482	52.418	54.673
Short Term Investments	19.554	38.208	29.534	39.192	53.978
Total Receivables, Net	0	0.342	0.717	0.944	1.246
Accounts Receivable - Trade, Net	0	0.342	0.717	0.944	1.246
Prepaid Expenses	3.462	3.908	6.011	4.413	5.181
Total Assets	51.629	66.577	83.116	101.794	121.516
Property/Plant/Equipment, Total - Net	1.405	2.164	3.038	3.938	4.825
Goodwill, Net
Intangibles, Net
Other Long Term Assets, Total	0.552	0.332	0.334	0.889	1.613
Total Current Liabilities	7.132	8.831	9.97	16.296	15.461
Accounts Payable	0.758	0.904	1.224	2.493	1.942
Accrued Expenses	6.374	7.927	8.746	13.803	13.519
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	9.915	11.628	12.783	19.13	19.112
Total Long Term Debt	0	0	0	0	0
Deferred Income Tax
Other Liabilities, Total	2.783	2.797	2.813	2.834	3.651
Total Equity	41.714	54.949	70.333	82.664	102.404
Common Stock	0.053	0.052	0.052	0.049	0.048
Additional Paid-In Capital	816.722	815.588	814.264	807.938	805.48
Retained Earnings (Accumulated Deficit)	-774.786	-760.366	-743.47	-724.52	-702.125
Unrealized Gain (Loss)	-0.275	-0.325	-0.513	-0.803	-0.999
Total Liabilities & Shareholders’ Equity	51.629	66.577	83.116	101.794	121.516
Total Common Shares Outstanding	52.6142	52.4507	52.0153	48.895	48.4812
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Long Term Investments				0	0
Property/Plant/Equipment, Total - Gross				5.625
Accumulated Depreciation, Total				-1.687
Total Preferred Shares Outstanding	0	0	0	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-93.092	-129.855	-62.152	-97.634	-90.751
Cash From Operating Activities	-84.463	-93.396	-62.957	-84.067	-64.958
Cash From Operating Activities	0.498	0.466	0.691	0.494	0.643
Deferred Taxes	0	-2.531	0	-0.774	1.099
Non-Cash Items	10.253	49.925	28.813	23.374	28.256
Changes in Working Capital	-2.122	-11.401	-30.309	-9.527	-4.205
Cash From Investing Activities	90.64	26.515	68.07	-50.318	-135.397
Capital Expenditures	-0.102	-3.096	-2.22	-1.554	-0.34
Other Investing Cash Flow Items, Total	90.742	29.611	70.29	-48.764	-135.057
Cash From Financing Activities	0.614	53.064	7.599	139.646	159.793
Issuance (Retirement) of Stock, Net	0.614	52.806	6.919	138.899	159.385
Net Change in Cash	6.791	-13.817	12.712	5.261	-40.562
Financing Cash Flow Items		0.258	0.68	0.747	0.408

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-18.95	-93.092	-70.697	-47.552	-23.091
Cash From Operating Activities	-23.428	-84.463	-65.209	-45.387	-27.502
Cash From Operating Activities	0.124	0.498	0.374	0.24	0.12
Non-Cash Items	2.638	10.253	7.458	5.022	2.485
Changes in Working Capital	-7.24	-2.122	-2.344	-3.097	-7.016
Cash From Investing Activities	10	90.64	74.078	42.646	33.049
Capital Expenditures		-0.102	-0.102	0	0
Other Investing Cash Flow Items, Total	10	90.742	74.18	42.646	33.049
Cash From Financing Activities	4.492	0.614	0.177	0.177	0
Issuance (Retirement) of Stock, Net	4.492	0.614	0.177	0.177	0
Net Change in Cash	-8.936	6.791	9.046	-2.564	5.547
Deferred Taxes		0
Financing Cash Flow Items

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Assembly Biosciences, Inc. Company profile

About Assembly Biosciences Inc

Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Assembly Biosciences Inc revenues decreased 92% to $6.3M. Net loss increased from $62.2M to $129.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and other income, net decrease of 88% to $302K (income), Restructuring Charges & Provisions increase of 40% to $277K (expense).

Equity composition

Common Stock $0.001 Par, 4/11, 25M auth., 7,189,706 issd.insider control 7.88%. 07-14, 1-for-5 reverse stock split.

Industry:

Proprietary & Advanced Pharmaceuticals

Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024